Capture of mesothelioma cells with ‘universal’ CTC-chip
- Kazue Yoneda
- Yasuhiro Chikaishi
- Taiji Kuwata
- Takashi Ohnaga
- Fumihiro Tanaka
Published online on: December 14, 2017
Malignant mesothelioma (MM) is a highly aggressive malignant tumor, predominantly associated with job‑related exposure to asbestos. Development of effective and non‑invasive modalities for diagnosis is an important issue in occupational medicine. Circulating tumor cells (CTCs), which are tumor cells that are shed from primary tumors and circulate in the peripheral blood, may be detected at an earlier stage than malignant tumors, and detection of CTCs may provide a novel insight into the diagnosis of MM. In a previous study evaluating clinical utility of CTCs, detected with a widely used system ‘CellSearch’, the authors indicated a significant however insufficient capability in the diagnosis of MM, suggesting need for a more sensitive system. Accordingly, the authors developed a novel microfluidic system to capture CTCs (CTC‑chip), and demonstrated that the CTC‑chip effectively captured MM cells (ACC‑MESO‑4) spiked in the blood by conjugating an anti‑podoplanin antibody. The results of the present study demonstrated that the CTC‑chip coated with the anti‑podoplanin antibody captured another MM cell (ACC‑MESO‑1). However, the capture efficiencies were lower than those for ACC‑MESO‑4. In addition, an anti‑mesothelin antibody was used to capture CTCs, however the CTC‑chip coated with the anti‑mesothelin antibody failed to effectively capture MM cells, possibly due to low mesothelin expression. Overall, the CTC‑chip may capture specific types of CTCs by conjugating any antibody against an antigen expressed on CTCs, and may be a useful system for the diagnosis of malignant tumors, including MM.